PCM
AVDL

Portolan Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Portolan Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-289,906
Closed -$4.78M – 126
2023
Q2 		$4.78M Buy
289,906
+1,581
+0.5% +$20.6K 0.42% 71
2023
Q1 		$2.64M Buy
+288,325
New +$2.37M 0.25% 109
2018
Q4 		– Sell
-150,600
Closed -$661K – 83
2018
Q3 		$661K Sell
150,600
-5,371
-3% -$29K 0.07% 94
2018
Q2 		$956K Sell
155,971
-54,041
-26% -$379K 0.1% 94
2018
Q1 		$1.53M Buy
+210,012
New +$1.85M 0.17% 90
2017
Q3 		– Sell
-130,311
Closed -$1.44M – 116
2017
Q2 		$1.44M Sell
130,311
-53,555
-29% -$538K 0.18% 105
2017
Q1 		$1.78M Sell
183,866
-95,485
-34% -$955K 0.23% 110
2016
Q4 		$2.9M Sell
279,351
-458,178
-62% -$5.04M 0.39% 91
2016
Q3 		$9.14M Sell
737,529
-124,765
-14% -$1.63M 1.26% 21
2016
Q2 		$9.26M Buy
862,294
+130,060
+18% +$1.39M 1.33% 18
2016
Q1 		$8.08M Sell
732,234
-311,058
-30% -$3.09M 1.08% 28
2015
Q4 		$12.7M Sell
1,043,292
-180,687
-15% -$2.82M 1.61% 13
2015
Q3 		$20M Buy
1,223,979
+328,507
+37% +$7.24M 2.65% 5
2015
Q2 		$19M Buy
+895,472
New +$16.1M 2.65% 3

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Portolan Capital Management's AVDL Position: Q3 2023 in Review

Portolan Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2023, closing a stake of 289,906 shares — an estimated $4.78M sold.

Portolan Capital Management first reported a position in AVDL in Q2 2015 and held it in 14 quarters. The position peaked at $20M in Q3 2015. 99 funds tracked by Wall St. Rank hold AVDL as of Q3 2023.

  • Portolan Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Portolan Capital Management sold 289,906 Avadel Pharmaceuticals shares in Q3 2023, an estimated $4.78M.
  • Portolan Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2015 and held it in 14 quarters.
  • Portolan Capital Management's Avadel Pharmaceuticals position peaked at $20M in Q3 2015.
  • 99 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2023.

Based on Portolan Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.